Safe Save Medical Cell Sciences & Technology Co

What Safe Save Medical Cell Sciences & Technology Co does

Safe Save Medical Cell Sciences & Technology Co., Ltd (SSMC, dba Safe Save Cell) is a Taiwan-based clinical-stage biotechnology company founded in 2011 that develops cancer immunotherapies centered on its proprietary ADCTA (Autologous Dendritic Cells/Tumor Antigens) platform. The company's process extracts monocytes from a patient's peripheral blood, differentiates them into dendritic cells in vitro, loads them with autologous tumor antigens enhanced by proprietary Knowhow, and re-administers the antigen-presenting cells to activate cytotoxic T lymphocyte responses against residual cancer cells. Manufacturing takes place at a PIC/S GMP- and GTP-compliant facility in the Hsinchu Biomedical Science Park meeting EU Grade C cleanliness standards.

The lead clinical candidate ADCTA-SSC-G1 is in a Taiwan TFDA-approved Phase III clinical trial as adjuvant immunotherapy for glioblastoma multiforme (GBM), recruiting 118 patients across seven Taiwanese medical centers including Chang Gung Memorial Hospital campuses (Linkou, Keelung, Chiayi, Kaohsiung), Veterans General Hospital Taichung, Chi Mei Hospital Tainan, and National Chen-Kung University Hospital. Phase I/II and Phase II data showed a five-year overall survival rate of 18.8% for the ADCTA-SSC-G1 group versus less than 5% for the reference group. The company is pursuing pipeline expansion into lung, colorectal, breast, ovarian, pancreatic, and prostate cancers and plans geographic expansion via overseas subsidiaries and turnkey out-licensing.

As a pre-commercial company, SSMC supplies its ADCTA therapeutic product at no charge to clinical trial sites and has not yet generated product revenue. The company is led by founder W.K. Yang, M.D., Ph.D., whose translational medicine background spans the U.S. National Institutes of Health and Academia Sinica, Taiwan. In January 2026, Nasdaq-listed YD Bio Limited signed a binding Letter of Intent to acquire SSMC for approximately US$26.87 million, subject to due diligence, which would represent a change of control for the company.

Name

Safe Save Medical Cell Sciences & Technology Co

Legal name

Safe Save Medical Cell Sciences & Technology Co., Ltd

Website

https://safesavecell.com

Company type

Private

Founded year

2011

Operating status

Operating

Short description

Safe Save Medical Cell Sciences & Technology Co is a Taiwan-based clinical-stage biotechnology company founded in 2011 developing ADCTA, an autologous dendritic cell immunotherapy, with lead candidate ADCTA-SSC-G1 in Phase III trials for glioblastoma across seven Taiwan medical centers.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy / Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dendritic Cell & Other APC-based Therapies (HLAAABAF)

akta.pro secondary industries

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

Keywords

• Cancer immunotherapy
• Autologous dendritic cells
• Cell therapy manufacturing
• Glioblastoma treatment
• Clinical stage biotechnology

Headquarters

HQ city

Taiwan

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Immunocellular Therapy Products & Clinical Development: As a pre-commercial clinical-stage biotechnology company, SSMC does not yet generate product revenue. Its primary value derives from its ADCTA immunotherapy pipeline and Phase III clinical trial data. Future revenue is expected from the commercialization of ADCTA as a routine medicine for multiple cancer indications pending TFDA approval, and/or through the planned acquisition by YD Bio Limited (valued at approximately US$26.87 million).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Safe Save Cell (SSC) develops and manufactures ADCTA, a personalized autologous dendritic cell immunotherapy platform, in which patient-derived monocytes are differentiated into dendritic cells, loaded with autologous tumor antigens using proprietary Knowhow, and reinfused to trigger cytotoxic T lymphocyte anti-cancer responses. Its lead clinical asset, ADCTA-SSC-G1, is in TFDA-approved Phase III trials in Taiwan for recurrent glioblastoma multiforme (GBM), with planned expansion to multiple solid tumor indications. Manufacturing is performed at a PIC/S GMP- and GTP-compliant facility in the Hsinchu Biomedical Science Park.

Product overview

Safe Save Medical Cell Sciences & Technology Co is a Taiwan-based biotechnology company founded in 2011, focused on cancer immunotherapy. The company's core offering is the ADCTA (Autologous Dendritic Cells/Tumor Antigens) technology platform, a proprietary precision medicine approach that uses a patient's own dendritic cells and tumor antigens. The primary therapeutic product is ADCTA-SSC-G1, an adjuvant immunotherapy for glioblastoma multiforme currently in Phase III clinical trials in Taiwan. The company is expanding its ADCTA platform to treat multiple solid tumor cancers including lung, colorectal, breast, ovarian, pancreatic, and prostate cancers. The company also provides immune cell storage services and operates a cGTP/cGLP HEPA-filtered barrier manufacturing facility compliant with PIC/S GMP specifications.

Differentiator

Problem solved

Functional benefit

Products and services

• ADCTA (Autologous Dendritic Cells/Tumor Antigens) Platform Proprietary tailormade cancer immunotherapy platform that uses a patient's own dendritic cells and tumor antigens to stimulate a targeted immune response against cancer cells. Monocytes are extracted from peripheral blood, differentiated into dendritic cells in vitro, loaded with enhanced autologous tumor antigens using proprietary Knowhow, and administered to activate cytotoxic T lymphocytes (CTL) for precise cancer targeting.
• ADCTA-SSC-G1 Autologous Dendritic Cells/Tumor Antigens (ADCTA-SSC-G1) adjuvant immunotherapy for Glioblastoma Multiforme (GBM). Currently in Phase III clinical trial in Taiwan with TFDA approval, having demonstrated 5-year overall survival of 18.8% for the ADCTA-SSC-G1 group versus less than 5% for the reference group in Phase I/II and Phase II trials.
• ADCTA Cancer Immunotherapy Pipeline Extension of the ADCTA immunotherapy platform to multiple solid cancer indications including metastatic lung cancer, colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Development leverages bioequivalence testing enabling direct progression to Phase II clinical trials.
• Immune Cell Storage Services Cell storage services covering isolation, processing, and storage of therapeutic-grade immunocytes including neutrophils, eosinophils, basophils, T cells, B cells, natural killer cells, monocytes, macrophages, and dendritic cells for therapeutic applications.
• Dendritic Cell Immunotherapy Immunotherapy approach utilizing dendritic cells' antigen-presenting capabilities to re-stimulate or reactivate cancer-killing T cells, suppressing cancer growth. Encompasses both passive immunity (allogeneic antibodies) and active immunity (cancer vaccines including tumor cell, tumor antigen, and cell antigen approaches).

Quantifiable outcome

• 5-Year overall survival rate of 18.8% for ADCTA-SSC-G1 group vs <5% for reference group in GBM Phase I/II and Phase II trials
• +2 more outcomes

Named customers7 records

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Chang Gung Memorial Hospital (Linkou, Keelung, Chiayi, Kaohsiung)coreStrategic or Co-development Partner · 1 January 2018SSMC collaborates with all four Chang Gung Memorial Hospital campuses (Linkou, Keelung, Chiayi, Kaohsiung) as Phase III clinical trial sites for ADCTA-SSC-G1 adjuvant immunotherapy of glioblastoma. Senior chief neurosurgeons at each hospital serve as principal investigators, with SSC providing the ADCTA therapeutic product free of charge. The collaboration represents the core of SSMC's Phase III trial program.
• Veterans General Hospital (Taichung)coreStrategic or Co-development Partner · 1 January 2018Veterans General Hospital Taichung serves as a Phase III clinical trial site for ADCTA-SSC-G1, with the senior chief neurosurgeon serving as principal investigator. SSC provides free ADCTA therapeutics prepared at its manufacturing facility.
• Chi Mei Hospital (Tainan)coreStrategic or Co-development Partner · 1 January 2018Chi Mei Hospital Tainan serves as a Phase III clinical trial site for ADCTA-SSC-G1, with the senior chief neurosurgeon serving as principal investigator. SSC provides free ADCTA therapeutics prepared at its manufacturing facility.
• National Chen-Kung University HospitalcoreStrategic or Co-development Partner · 1 January 2018National Chen-Kung University Hospital serves as a Phase III clinical trial site for ADCTA-SSC-G1, with the senior chief neurosurgeon serving as principal investigator. SSC provides free ADCTA therapeutics prepared at its manufacturing facility.
• Chung Shan Medical University HospitalminorStrategic or Co-development PartnerSSMC collaborates with Chung Shan Medical University Hospital on the 'Development of Anticancer Efficacy Detection Platform for Cancer Stem Cell Surface Antigens' project. This industry-academy program has gained recognition and support from the Hsinchu Science Park R&D Intensive Industry-Academy Program, contributing to ADCTA efficacy enhancement and expansion to additional cancer indications.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Kazia Therapeutics: Commercial and clinical-stage oncology company developing paxalisib for newly diagnosed and recurrent GBM, plus broader brain cancer pipeline. Same lead indication as ADCTA-SSC-G1, but small-molecule rather than cell therapy.
• Novartis (Kymriah): Global pharma with Kymriah, the first FDA-approved CAR-T therapy, plus a broader cell and gene therapy portfolio. Provides the regulatory, manufacturing, and commercial benchmark against which any autologous cell therapy — including ADCTA — must compete.
• Kite Pharma (Gilead): Developer of Yescarta and Tecartus, leading CAR-T therapies in large B-cell lymphoma and mantle cell lymphoma. A global cell therapy incumbent whose autologous manufacturing scale and commercial footprint define the bar for any emerging autologous platform like ADCTA.

Direct peers

• Dendreon: Marketed Provenge (sipuleucel-T), the first FDA-approved autologous cellular immunotherapy, for metastatic castration-resistant prostate cancer. Closest commercial analog to a patient-specific autologous dendritic cell product and the de facto benchmark for ADCTA's commercial trajectory.
• Northwest Biotherapeutics: Developer of DCVax-L, an autologous dendritic cell vaccine for glioblastoma and other solid tumors. The closest direct peer to ADCTA-SSC-G1, with a shared autologous DC vaccine mechanism of action and an identical GBM lead indication.
• SOTIO Biotech: Clinical-stage developer of DCVAC, an autologous dendritic cell vaccine platform evaluated in prostate, ovarian, and lung cancers. Shares SSMC's autologous DC vaccine architecture across multiple solid tumor indications.
• AIVITA Biomedical: Clinical-stage biotech developing AV-GBM-1, an autologous dendritic cell vaccine for newly diagnosed glioblastoma. Directly comparable to ADCTA in modality (patient-derived DCs loaded with tumor antigens) and primary indication (GBM).

Others

• YD Bio Limited: Nasdaq-listed biotechnology company that signed a binding LOI in January 2026 to acquire SSMC for ~US$26.87M. Included as a directly relevant ecosystem participant — the proposed acquirer and potential commercialization vehicle for the ADCTA platform.

Emerging players

• Immunicum: Swedish developer of ilixadencel, an allogeneic dendritic cell-based immune primer for solid tumors. Adjacent mechanism (dendritic cell immunotherapy in oncology) but uses off-the-shelf allogeneic cells rather than SSMC's patient-derived autologous approach.

Regional players

• JW Therapeutics: China-based clinical- and commercial-stage cell therapy company focused on CAR-T products for hematologic malignancies. Comparable as an Asia-based autologous cell therapy player targeting regional regulatory pathways, though with a different modality than ADCTA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Safe Save Medical Cell Sciences & Technology Co